PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders (157)
The purpose of this observational study is to give an overview of the use of PASCOE-Agil HOM-Injektopas in a 2-4 week treatment of rheumatic disorders of different aetiology and localisation, displaying a variety of symptoms.
Efficacy and tolerability of the drug will be assessed. Special regard will be taken to the administration management in relation to the Summary of Product Characteristics (SmPC).
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders: A Non-interventional Observational Study.|
- Efficacy of the drug, measured by decrease in disease-related symptoms, (Visual Analog Scale (VAS)) [ Time Frame: Beginning, 2 + 4 weeks ] [ Designated as safety issue: No ]
- Tolerability of the drug, measured by documentation of adverse drug reactions (ADR) [ Time Frame: from enrollment until completion ] [ Designated as safety issue: Yes ]
- Acceptance of the drug by medical personnel and patients [ Time Frame: from enrollment until completion ] [ Designated as safety issue: Yes ]
|Study Start Date:||January 2009|
|Study Completion Date:||May 2009|
|Primary Completion Date:||May 2009 (Final data collection date for primary outcome measure)|
Patients suffering from rheumatic disorders of different types and origins, especially those with arthralgia, myalgia, lumbago, or other diagnoses.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00922428
|Study Director:||Anja Braschoss, MD||Pascoe Pharmazeutische Praeparate GmbH|